medigraphic.com
Colegio de Medicina Interna de México.

2025, Número 04

<< Anterior Siguiente >>

Med Int Mex 2025; 41 (04)


Tegoprazan: evidencia y utilidad en la práctica clínica del tratamiento de las enfermedades relacionadas con el ácido

Remes TJM, Vargas BJL

Idioma: Español
Referencias bibliográficas: 49
Paginas: 234-249
Archivo PDF: 433.84 Kb.


RESUMEN

Antecedentes: Los bloqueadores ácidos competitivos de potasio (P-CAB) representan una clase innovadora de medicamentos prescritos para tratar las enfermedades relacionadas con la secreción de ácido gástrico, como la enfermedad por reflujo gastroesofágico y las úlceras pépticas. El tegoprazan es un benzimidazol y es el primer bloqueador de ácidos competitivos de potasio disponible en México.
Objetivo: Analizar la evidencia clínica disponible de esta molécula.
Metodología: Búsqueda cruzada a través de los portales de PubMed e Imbiomed (hasta febrero de 2024) de los siguientes términos (en español y sus respectivas traducciones y abreviaturas en inglés): tegoprazan, úlceras, Helicobacter pylori, reflujo gastroesofágico.
Resultados: De 62 artículos obtenidos en la búsqueda se incluyó la información proveniente de 49. El tegoprazan supera las limitaciones de los inhibidores de la bomba de protones gracias a su vida media más larga y un inicio de acción más rápido (a partir de los 15-30 minutos de su ingestión). Tiene una evidencia sólida en términos de seguridad y eficacia. Su eficacia clínica está demostrada en el tratamiento de la enfermedad por reflujo erosiva y de la úlcera gastroduodenal y es una excelente opción en la optimización de la erradicación de la infección por Helicobacter pylori.
Conclusiones: El tegoprazan es un tratamiento eficaz contra las enfermedades relacionadas con el ácido y tiene ventajas farmacológicas en comparación con los inhibidores de la bomba de protones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sobrino-Cossío S, Teramoto-Matsubara O, Mateos-Pérez G,Abdo-Francis JM, et al. In search of the grail: A race for acidsuppression. Rev Gastroenterol Mex 2019; 84 (3): 344-56.https://doi.org.10.1016/j.rgmx.2019.04.002

  2. He J, Cao G, Yu J, Wang J, et al. Safety, tolerability andpharmacokinetics of single ascending and multiple oraldoses of tegoprazan in healthy chinese subjects. Clin DrugInvestig 2021; 41 (1): 89-97. https://doi.org.10.1007/s40261-020-00986-4

  3. Abdel-Aziz Y, Metz DC, Howden CW. Review article:potassium-competitive acid blockers for the treatment ofacid-related disorders. Aliment Pharmacol Ther 2021; 53(7): 794-809. https://doi.org.10.1111/apt.16295

  4. Chen D, Hagen SJ, Boyce M, Zhao CM. Neuroendocrinemechanism of gastric acid secretion: Historical perspectivesand recent developments in physiology and pharmacology.J Neuroendocrinol 2023; 35 (11): e13305. https://doi.org.10.1111/jne.13305

  5. Engevik AC, Kaji I, Goldenring JR. The physiology of thegastric parietal cell. Physiol Rev 2020; 100 (2): 573-602.https://doi.org.10.1152/physrev.00016.2019

  6. Ramsay PT, Carr A. Gastric acid and digestive physiology.Surg Clin North Am 2011; 91 (5): 977-82. https://doi.org.10.1016/j.suc.2011.06.010

  7. Sachs G, Shin JM, Howden CW. Review article: the clinicalpharmacology of proton pump inhibitors. Aliment PharmacolTher 2006; 23 Suppl 2: 2-8. https://doi.org.10.1111/j.1365-2036.2006.02943.x

  8. Sachs G, Shin JM, Pratha V, Hogan D. Synthesis or rupture:duration of acid inhibition by proton pump inhibitors. DrugsToday (Barc) 2003; 39 Suppl A: 11-4.

  9. Hunt RH, Scarpignato C. Potent acid suppression with PPIsand P-CABs: What’s new? Curr Treat Options Gastroenterol2018; 16 (4): 570-590. https://doi.org.10.1007/s11938-018-0206-y

  10. Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphismof CYP2C19 & therapeutic response to proton pump inhibitors.Indian J Med Res 2008; 127 (6): 521-30.

  11. Leowattana W, Leowattana T. Potassium-competitiveacid blockers and gastroesophageal reflux disease. WorldJ Gastroenterol 2022; 28 (28): 3608-3619. https://doi.org.10.3748/wjg.v28.i28.3608

  12. Oshima T, Miwa H. Potent potassium-competitive acidblockers: A new era for the treatment of acid-related diseases.J Neurogastroenterol Motil 2018; 24 (3): 334-344.https://doi.org.10.5056/jnm18029

  13. Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment ofgastroesophageal reflux disease. Curr Opin Gastroenterol2019; 35 (4): 344-355. https://doi.org.10.1097/MOG.0000000000000543

  14. Kim DK, Lee KH, Kim SJ, Kim SJ, et al . Effects of tegoprazan,a novel potassium-competitive acid blocker, on ratmodels of gastric acid-related disease. J Pharmacol ExpTher 2019; 369 (3): 318-327. https://doi.org.10.1124/jpet.118.254904

  15. Tanaka S, Morita M, Yamagishi T, Madapally HV, et al.Structural basis for binding of potassium-competitiveacid blockers to the gastric proton pump. J Med Chem2022; 65 (11): 7843-7853. https://doi.org.10.1021/acs.jmedchem.2c00338

  16. Jeong HC, Kim MG, Wei Z, Lee KR, et al. Integration of aphysiologically based pharmacokinetic and pharmacodynamicmodel for tegoprazan and its metabolite: applicationfor predicting food effect and intragastric pH alterations.Pharmaceutics 2022; 14 (6): 1298. https://doi.org.10.3390/pharmaceutics14061298

  17. Yoon DY, Lee S, Jang IJ, Kim M, et al. Prediction of drug–druginteraction potential of tegoprazan using physiologicallybased pharmacokinetic modeling and simulation. Pharmaceutics2021; 13 (9): 1489. https://doi.org.10.3390/pharmaceutics13091489

  18. Jeon JY, Kim SY, Moon SJ, Oh K, et al. Pharmacokineticinteractions between tegoprazan and metronidazole/tetracycline/bismuth and safety assessment in healthy Koreanmale subjects. Clin Ther 2021; 43 (4): 722-734. https://doi.org.10.1016/j.clinthera.2021.01.026

  19. Oh M, Lee H, Kim S, Kim B, et al. Evaluation of pharmacokineticdrug-drug interaction between tegoprazan and clarithromycinin healthy subjects. Transl Clin Pharmacol 2023;31 (2): 114-123. https://doi.org.10.12793/tcp.2023.31.e11

  20. Moon SJ, Shin N, Kang M, Kim B, Kim MG. Pharmacokineticinteractions between tegoprazan and naproxen, aceclofenac,and celecoxib in healthy Korean male subjects. ClinTher 2022; 44 (7): 930-944.e1. https://doi.org.10.1016/j.clinthera.2022.06.002

  21. Kim MG, Im YJ, Lee JH, Kim EY, et al. Comparison of hepatotoxicityof tegoprazan, a novel potassium-competitive acidblocker, with proton pump inhibitors using real-world data:A nationwide cohort study. Front Med (Lausanne) 2023;9: 1076356. https://doi.org.10.3389/fmed.2022.1076356

  22. Hong J Taek, Yoon H Jeon, et al. ep124 effects of tegoprazan,potassium competitive acid blocker, on thegastric emptying: a pilot study. Gastroenterology 2023;164 (6): S-1213-S-1214. https://doi.org/10.1016/S0016-5085(23)03807-6

  23. Bosques-Padilla FJ, Remes-Troche JM, González-Huezo MS,Pérez-Pérez G, et al . The fourth Mexican consensus on Helicobacterpylori. Rev Gastroenterol Mex (Engl Ed) 2018; 83(3): 325-341. https://doi.org.10.1016/j.rgmx.2018.05.003

  24. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, et al;European Helicobacter and Microbiota Study group. Managementof Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022: gutjnl-2022-327745.https://doi.org.10.1136/gutjnl-2022-327745

  25. Kim TH. Role of potassium-competitive acid blockers ineradication of Helicobacter pylori infection. Korean J InternMed 2023; 38 (4): 451-453. https://doi.org.10.3904/kjim.2023.250

  26. Shah A, Usman O, Zahra T, Chaudhari SS, Mulaka GSR,et al. Efficacy and safety of potassium-competitive acidblockers versus proton pump inhibitors as Helicobacterpylori eradication therapy: A meta-analysis of randomizedclinical trials. Cureus 2023; 15 (11): e48465. https://doi.org.10.7759/cureus.48465

  27. Jeon JY, Kim SY, Moon SJ, Oh K, et al. Pharmacokineticinteractions between tegoprazan and metronidazole/tetracycline/bismuth and safety assessment in healthy koreanmale subjects. Clin Ther 2021; 43 (4): 722-734. https://doi.org.10.1016/j.clinthera.2021.01.026

  28. Park CH, Park JH, Jung YS. Comparative efficacy of tegoprazanvs esomeprazole/sodium bicarbonate for the treatmentof Helicobacter pylori infection. Clin Transl Gastroenterol2023; 14 (11): e00632. https://doi.org.10.14309/ctg.0000000000000632

  29. Kwon YH, Jeon SW, Nam SY, Lee DW, et al. Ten-day tegoprazan-based concomitant therapy as a first-line treatment forHelicobacter pylori eradication. Korean J Intern Med 2023;38 (4): 493-503. https://doi.org.10.3904/kjim.2022.345.

  30. Kim JS, Ko W, Chung JW, Kim TH. Efficacy of tegoprazanbasedbismuth quadruple therapy compared with bismuthquadruple therapy for Helicobacter pylori infection: A randomized,double-blind, active-controlled study. Helicobacter2023; 28 (3): e12977. https://doi.org.10.1111/hel.12977

  31. Jung YS, Kim S, Kim HY, Noh SJ, et al. Efficacy and tolerabilityof 14-day tegoprazan- versus rabeprazole-based tripletherapy for eradication of Helicobacter pylori: A real-worldevidence study. Gut Liver 2023; 17 (5): 711-721. https://doi.org.10.5009/gnl220218

  32. Park CH, Song MJ, Jung BW, Park JH, Jung YS. Comparativeefficacy of 14-day tegoprazan-based triple vs. 10-daytegoprazan-based concomitant therapy for Helicobacterpylori eradication. J Pers Med 2022; 12 (11): 1918. https://doi.org.10.3390/jpm12111918

  33. Jung YS, Kim S, Kim HY, Noh SJ, et al. 7-day versus 14-daytegoprazan-based triple therapy to treat Helicobacterpylori infection: Real-world evidence. J GastroenterolHepatol 2022; 37 (10): 1911-1918. https://doi.org.10.1111/jgh.15939

  34. Choi YJ, Lee YC, Kim JM, Kim JI, et al. Triple therapy-basedon tegoprazan, a new potassium-competitive acid blocker,for first-line treatment of Helicobacter pylori infection: Arandomized, double-blind, phase III, clinical trial. Gut Liver2022; 16 (4): 535-546. https://doi.org.10.5009/gnl220055

  35. Kim JY, Lee SY, Kim H, Kim JH, Sung IK, Park HS. Efficacy ofseven-day potassium-competitive acid blocker-based firstlineHelicobacter pylori eradication therapy administeredwith bismuth. Yonsei Med J 2021; 62 (8): 708-716. https://doi.org.10.3349/ymj.2021.62.8.708

  36. Huerta-Iga F, Bielsa-Fernández MV, Remes-Troche JM,Valdovinos-Díaz MA, Tamayo-de la Cuesta JL; en representacióndel Grupo para el estudio de la ERGE 2015.Diagnosis and treatment of gastroesophageal refluxdisease: recommendations of the Asociación Mexicanade Gastroenterología. Rev Gastroenterol Mex 2016; 81(4): 208-222. https://doi.org.10.1016/j.rgmx.2016.04.003

  37. Devault KR, Johanson JF, Johnson DA, Liu S, Sostek MB.Maintenance of healed erosive esophagitis: a randomizedsix-month comparison of esomeprazole twenty milligramswith lansoprazole fifteen milligrams. Clin GastroenterolHepatol 2006; 4 (7): 852-9. https://doi.org.10.1016/j.cgh.2006.03.006

  38. Shin CM, Choi SC, Cho JW, Kim SY, et al. Comparison of tegoprazanand lansoprazole in patients with erosive esophagitis:a multicenter, randomized, double-blind, activecomparatorphase 4 trial. Gastroenterology 2023; 164 (6):S-204. https://doi.org/10.1016/S0016-5085(23)01449-X

  39. Lee KJ, Son BK, Kim GH, Jung H, et al. Randomised phase3 trial: tegoprazan, a novel potassium‐competitive acidblocker, vs. esomeprazole in patients with erosive oesophagitis.Aliment Pharmacol Ther 2019; 49 (7): 864-872.https://doi.org/10.1111/apt.15185

  40. Cho YK, Kim JH, Kim HS, Kim TO, et al. Randomised clinicaltrial: comparison of tegoprazan and lansoprazole asmaintenance therapy for healed mild erosive oesophagitis.Aliment Pharmacol Ther 2023; 57 (1): 72-80. https://doi.org/10.1111/apt.17255

  41. Kim JS, Seo SI, Kang SH, Lee SK, et al. Effects of tegoprazanversus esomeprazole on nighttime heartburn and sleepquality in gastroesophageal reflux disease: a multicenterdouble-blind randomized controlled trial. J NeurogastroenterolMotil 2023; 29 (1): 58-64. https://doi.org/10.5056/jnm22104

  42. Han S, Choi HY, Kim YH, Choi S, et al. Comparison of pharmacodynamicsbetween tegoprazan and dexlansoprazoleregarding nocturnal acid breakthrough: A randomizedcrossover study. Gut Liver 2023; 17 (1): 92-99. https://doi.org/10.5009/gnl220050

  43. Yang E, Kim S, Kim B, Kim B, et al. Night‐time gastric acidsuppression by tegoprazan compared to vonoprazan oresomeprazole. Br J Clin Pharmacol 2022; 88 (7): 3288-3296.https://doi.org/10.1111/bcp.15268

  44. Kim SH, Cho KB, Chun HJ, Lee SW, et al . Randomised clinicaltrial: comparison of tegoprazan and placebo in non-erosivereflux disease. Aliment Pharmacol Ther 2021; 54 (4): 402-411. https://doi.org/10.1111/apt.16477

  45. Laine L, Jensen DM. Management of patients with ulcerbleeding. Am J Gastroenterol 2012; 107: 345-360. https://doi.org/10.1038/ajg.2011.480

  46. Lanas A, Chan FKL. Peptic ulcer disease. Lancet 2017;390 (10094): 613-624. https://doi.org/10.1016/S0140-6736(16)32404-7

  47. Dong Y, Xu H, Zhang Z, Zhou Z, Zhang Q. Comparative efficiencyand safety of potassium competitive acid blockersversus Lansoprazole in peptic ulcer: a systematic reviewand meta-analysis. Front Pharmacol 2024; 14: 1304552.https://doi.org/10.3389/fphar.2023.1304552

  48. Cho YK, Choi MG, Choi SC, Lee KM, et al. Randomised clinicaltrial: tegoprazan, a novel potassium-competitive acidblocker, or lansoprazole in the treatment of gastric ulcer.Aliment Pharmacol Ther 2020; 52 (5): 789-797. https://doi.org/10.1111/apt.15865

  49. Kim BW, Park JJ, Moon HS, Lee WS, et al . The effect of tegoprazanon the treatment of endoscopic resection-inducedartificial ulcers: a multicenter, randomized, active-controlledstudy. Gut Liver 2024. https://doi.org/10.5009/gnl230242




2020     |     www.medigraphic.com